StockStory.org on MSN
BIIB Q4 deep dive: Pipeline advances and new product launches offset legacy headwinds
Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results , but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus ...
Hosted on MSN
Merck outlines $50B growth opportunity by mid-2030s as pipeline and new launches accelerate
CEO Robert Davis stated that "We continue to make meaningful progress in using the power of leading-edge science to save and improve lives around the world," highlighting approximately 80 Phase III ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of the fastest-growing penny stocks to buy now. On November 18 at the Jefferies London Healthcare Conference 2025, Lexicon Pharmaceuticals (NASDAQ:LXRX) ...
Christopher Viehbacher, President and CEO, highlighted "a very strong third quarter," emphasizing launch products' year-over-year growth of 67%. He stated, "The launch products again in this quarter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results